¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"complement consumption test"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® Rorschach Test ÇÑ±Û ·Î¸£»þÇÏ °Ë»ç
¼³¸í   
  »ç°íÀå¾Ö¿Í Á¤¼­Àå¾Ö¿¡ ¹Î°¨ÇÑ Åõ»ç°Ë»ç(projective test). °ËÀº»ö°ú ¸î°¡Áö »öÀ¸·Î ÀÌ·ç¾îÁø À×Å©¾ó·è°°Àº µµÇüÀÌ ±×·ÁÁø 10°³ÀÇ Ä«µå¸¦ ÀÌ¿ëÇÑ´Ù. ÇǰËÀÚ¿¡°Ô Ä«µå¸¦ º¸ÀÌ°í º» °Í¿¡ ´ëÇØ ¸»Çϵµ·Ï ÇÑ´Ù. ´ÙÀ½¿¡´Â ¾ó·èÀÇ ¾î´À À§Ä¡°¡ ÇǰËÀÚ°¡ ¸»ÇÑ Áö°¢´ë»óÀ» ¾Ï½ÃÇÏ´ÂÁö Ã£µµ·Ï ÇÑ´Ù. ÇǰËÀÚÀÇ ´äº¯À» ºÐ¼®Çϸ頱×ÀÇ »ç°í¿Í Á¤¼­»óÅ¿¡ ´ëÇÑ Á¤º¸¸¦ ¾òÀ» ¼ö ÀÖ´Ù. 
¿µ¹® Mantoux test ÇÑ±Û ¸ÁÅä¿ì°Ë»ç
¼³¸í   
  ¼Ò¾Æ¿¡ ÁַΠ½Ç½ÃÇϴ °Ë»ç ¹æ¹ýÀ¸·Î, BCGÁ¢Á¾ÈÄ¿¡³ª È¤Àº °áÇÙ±Õ¿¡ ÇѹøÀ̶󵵠³ëÃâµÈ °æ¿ì¿¡ ¾ç¼º¹ÝÀÀÀ¸·Î ³ª¿Â´Ù. ¿ì¸®³ª¶ó¿¡¼­´Â »ýÈÄ 1°³¿ù¿¡ BCG¿¹¹æÁ¢Á¾À» ½ÃÇàÇϹǷΠ´ëºÎºÐ ¾ç¼ºÀ¸·Î ³ª¿À°Ô µÇ³ª, ÀÌ ¿¹¹æÁ¢Á¾À» ¹ÞÁö ¾ÊÀº »óÅ¿¡¼­ ¾ç¼ºÀ¸·Î ³ª¿À¸é, °áÇÙ±ÕÀǠħÅõ¸¦ ÀǽÉÇÒ ¼ö ÀÖ´Ù.
¿µ¹® stress test ÇÑ±Û ½ºÆ®·¹½º °Ë»ç
¼³¸í   
  Çù½ÉÁõÀÌ ÀϾ±â ½¬¿î È¯ÀÚ¿¡°Ô¼­ ±× Á¤µµ¸¦ ÆÇ´ÜÇϱâÀ§ÇØ ½ÃÇàÇÑ´Ù. ¹æ¹ýÀº °°Àº °÷¿¡¼­ È¯ÀÚ¸¦ ´Þ¸®µµ·Ï ÇÑ ´ÙÀ½, ¾ó¸¶ÀÇ ¼Óµµ¿¡¼­ Ç÷¾ÐÀÌ ¶³¾îÁö°í Çù½ÉÁõ Áõ»óÀÌ ³ªÅ¸³ª´Â°¡¸¦ °Ë»çÇÑ´Ù.
  
  ´ë°³ ½ÉÇÒ¼ö·Ï ³·Àº ¼Óµµ¿¡¼­µµ Áõ»óÀÌ »¡¸® ³ªÅ¸³­´Ù.
¿µ¹® visual field test ÇÑ±Û ½Ã¾ß°Ë»ç
¼³¸í   
  ´«À» ÇѰ÷¿¡ °íÁ¤½ÃŲ Ã¤, °üÂûÇÒ ¼ö Àִ ÁÖº¯°ø°£À» ½Ã¾ß¶ó ÇÑ´Ù. ½Ã¾ß¸¦ °Ë»çÇϴ °¡Àå °£´ÜÇÑ ¹æ¹ýÀº ´ë¸é°Ë»ç(confronting test)ÀÌ´Ù. À̰ÍÀº Çǰ˻çÀÚÀÇ ´«À» °Ë»çÀÚÀÇ ´«¿¡ ¸ÂÃ߾¸µµ·Ï ÇÏ¿© ´«À» °íÁ¤½ÃŲä, °Ë»çÀÚ°¡ ¼Õ°¡¶ô³¡À» À§ÂÊ, ¾Æ·¡ÂÊ, ¿ÞÂÊ, ¿À¸¥ÂÊ, ±×¸®°í ºñ½ºµëÈ÷ °æ»çÁø °÷ µîÀ¸·Î ¿Å°Üº¸¾Æ Çǰ˻çÀÚ°¡ °üÂûÇÒ ¼ö ÀÖ´ÂÁö ¿©ºÎ¸¦ Á¤Çϴ °Ë»ç¹ýÀÌ´Ù. À̺¸´Ù Á¤È®ÇÑ °Ë»ç¹ýÀº ÀÚµ¿½Ä ÄÄÇ»Åͽþ߰˻ç¹ýÀÌ ÀÖ´Ù. ´ë°³, ´«ÀÚüÀÇ ÀÌ»óÀÌ À־ ½Ã¾ß°Ë»ç¿¡¼­ ÀÌ»óÀÌ ³ª¿ÀÁö¸¸, À̿ܠ³úÀÇ ÀÌ»óÀ¸·Î ½Ã°¢ÀÇ Çü¼º°æ·Î¿¡ ÀÌ»óÀÌ À־ ¿ª½Ã ÀÌ»ó¼Ò°ßÀ» º¸ÀδÙ.
¿µ¹® Draw a person test ÇÑ±Û Àι°È­ ¼º°Ý°Ë»ç
¼³¸í   
  Àι°È­ ¼º°Ý°Ë»ç´Â Ã³À½¿¡´Â Áö´É°Ë»ç·Î °³¹ßµÇ¾ú°í, ±× ÈÄ¿¡´Â »ç¶÷ÀÇ ¹«ÀǽÄÀÇ ¿ä¼Ò¸¦ °Ë»çÇϴ ¹æ¹ýÀ¸·Î ¹ßÀüÇÏ¿´´Ù. °Ë»çÀç·á´Â Áö¿ì°³°¡ Àִ ¿¬Çʰú ¹éÁö¸¦ ÇǰËÀÚ¿¡°Ô ÁÖ°í, »ç¶÷À» ±×·Áº¸¶ó´Â Áö½Ã¸¦ Çϸç, °Ë»çÀڴ ±×¸®´Â ¼ø¼­¿Í Æò°¡¸¦ ±â·ÏÇϰí, ´Ù ±×¸° ÈÄ¿¡´Â ¸ÕÀú¿Í ´Ù¸¥ À̼ºÀ» ±×¸®µµ·Ï ÇÑ´Ù. ÀÌ °Ë»ç¿¡¼­ÀÇ ½ÅüÀÇ ¸ð¾çÀº °ð ÀھƻóÀ» ¹Ý¿µÇѴٴ ÀÔÀå, ±×¸²¿¡¼­ °­Á¶µÈ ±â°üÀº ÀÇ»ç¼ÒÅë¼ö´Ü, °ü³äÈ­, ¿å±¸Ã¼°è, ¼ºÀû ´É·Â, °¥µî, ÁÂÀý°æÇè, ¼ºÀå·Â µîÀ» ¹Ý¿µÇÑ´Ù°í ÇÑ´Ù. À̰ÍÀº ¾Æµ¿°ú ¼ºÀο¡°Ô °³º°Àû ¶Ç´Â Áý´ÜÀûÀ¸·Î ½Ç½ÃÇÒ ¼ö ÀÖ°í, °£ÆíÇϸ鼭µµ À¯ÀÍÇÑ °ÍÀÌ´Ù. ÀÓ»óÀûÀ¸·Î´Â ³úÀÇ ±âÁúÀû º¯È­¸¦ ¾Ë¾Æ³»±â À§ÇÑ ¸ñÀûÀ¸·Îµµ ¸¹ÀÌ ÀÌ¿ëµÈ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • complement inhibitor
    º¸Ã¼¾ïÁ¦Á¦, µµ¿òü¾ïÁ¦Á¦
  • complement mediated lysis
    º¸Ã¼¸Å°³¿ëÇØ, µµ¿òü¸Å°³¿ëÇØ
  • complement profile
    º¸Ã¼Ãø¸é»ó
  • complement receptor
    º¸Ã¼¼ö¿ëü
  • complement system
    º¸Ã¼°è, µµ¿òü°èÅë
  • complement-dependent cytotoxicity
    º¸Ã¼ÀÇÁ¸¼¼Æ÷µ¶¼º
  • complement-fixing antibody
    º¸Ã¼°áÇÕÇ×ü, µµ¿òü°áÇÕÇ×ü
  • complement-induced
    º¸Ã¼À¯µµ-
  • complement-mediated
    º¸Ã¼¸Å°³-
  • complement-mediated cytotoxicity
    º¸Ã¼¸Å°³¼¼Æ÷µ¶¼º
  • dominant complement
    ¿ì¼ºº¸Ã¼
  • acceptance test
    Àμö°Ë»ç
  • antibody identification test
    Ç×üȮÀΰ˻ç
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
  • anticholinesterase test
    Ç×Äݸ°¿¡½ºÅ×¶ó¾ÆÁ¦°Ë»ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • blood test
    Ç÷¾×°Ë»ç
  • blood coagulation test
    Ç÷¾×ÀÀ°í°Ë»ç
  • blood sugar test
    Ç÷´ç°Ë»ç
  • bronchial provocation test
    ±â°üÁöÀ¯¹ß°Ë»ç
  • contraction stress test
    ¼öÃàÀڱذ˻ç
  • Coombs' test
    (¢¡antiglobulin test) ÄñÁî°Ë»ç
  • creatinine clearance test
    Å©·¹¾ÆÆ¼´Ñû¼ÒÀ²°Ë»ç
  • D-xylose test
    Å©½Ç·Î¿À½º°Ë»ç
  • dip-stick test
    ¿ä½ÃÇèÁö°Ë»ç
  • estrogen challenge test
    ¿©¼ºÈ£¸£¸óºÎÇϰ˻ç
  • flashlight swinging test
    ±³´ëºÒºû°Ë»ç
  • glucose tolerance test
    ´çºÎÇϰ˻ç
  • guaiac test
    ÀáÇ÷°Ë»ç
  • Ham's test
    Çܰ˻ç
  • hemagglutination test
    Ç÷±¸ÀÀÁý½ÃÇè, Ç÷±¸ÀÀÁý°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • complement-induced
    (¢¡complement-mediated) µµ¿òü¸Å°³-
  • complement-mediated
    µµ¿òü¸Å°³-
  • classic complement pathway
    º¸Ã¼ÀüÇüÀû°æ·Î, µµ¿òüÀüÇüÀû°æ·Î
  • complement cascade
    º¸Ã¼¿¬¼âÁõÆø¹ÝÀÀ
  • complement component
    µµ¿òü¼ººÐ
  • complement deficiency
    µµ¿òü°áÇÌ
  • complement fixation
    µµ¿òü°áÇÕ
  • complement inhibitor
    º¸Ã¼¾ïÁ¦Á¦, µµ¿òü¾ïÁ¦Á¦
  • complement profile
    µµ¿òÃ¼Ãø¸é»ó
  • complement receptor
    µµ¿òü¼ö¿ëü, º¸Ã¼¼ö¿ëü
  • complement splitting
    µµ¿òüºÐ¿­, º¸Ã¼ºÐ¿­
  • complement system
    µµ¿òü°èÅë, º¸Ã¼°èÅë
  • complement typing
    º¸Ã¼Çüº°°Ë»ç
  • complement deficient state
    µµ¿òü°áÇÌ»óÅÂ, º¸Ã¼°áÇÌ»óÅÂ
  • complement fixation reaction
    º¸Ã¼°áÇÕ¹ÝÀÀ, µµ¿òü°áÇÕ¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • VDRL test= venereal disease research laboratory test
    ¼ºº´¿¬±¸¼Ò½ÄÅ×½ºÆ®.
  • acidified serum test=Ham test
    »ê¼ºÈ­Ç÷û°Ë»ç
  • acidified-serum lysis test=Ham test
    »ê¼ºÈ­Ç÷û¿ëÇ÷°Ë»ç
  • antiglobulin test = Coombs test
    Çױ۷κҸ°°Ë»ç
  • polyethylene glycol test =PEG test
    Æú¸®¿¡Æ¿·»±Û¸®Äݰ˻ç
  • ACTH stimulation test
    ACTH Àڱذ˻ç
  • Ames test
    ¿¡ÀÓ½º½ÃÇè
  • Ascolis test
    ¾Æ½ºÄݸ®½ÃÇè
  • Bacitracin differential disk test
    ¹Ù½ÃÆ®¶ó½Å°¨º°(¿ø)ÆÇ(÷ù)½ÃÇè
  • Bender-Gestalt test
    º¥´õ-°Ô½´Å»Æ® °Ë»ç
  • Benedict test
    º£³×µñÆ®½ÃÇè
  • Bentonite flocculation test
    º¥Å䳪ÀÌÆ® ¸é»óħÀü¹ý
  • Blondheim test
    ºí·ÐµåÇÏÀÓ½ÃÇè
  • Bonsignore test
    º»½Ã±×³ë½ÃÇè
  • C-Stix test
    C-½ºÆ½½º½ÃÇè<<¾Æ½ºÄÚ¸£ºó»ê½ÃÇè>>
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • consumption
    ¼Òºñ, ¼Ò¸ð(á¼ÙÄ).
  • consumption coagulopathy
    ¼Ò¸ð¼º ÀÀ°íº´Áõ(¡­àõëêͳܻñø).
  • consumption coagulopathy
    ¼Ò¸ð¼º ÀÀ°í ÀÌ»óÁõ(á¼ÙÄàõëêͳì¶ßÈñø)
  • consumption disease
    ¼Ò¸ð¼º Áúȯ.
  • line of consumption
    ¼Ò¸ð¼±(ËÛËÎËÛ).
  • luxus consumption
    °úµµ¼Ò¸ð(Φöôá¼ÙÄ).
  • mass consumption
    ¹ü¿ë.
  • maximum oxygen consumption
    ÃÖ´ë»ê¼Ò¼Ò¸ð·®.
  • myocardial oxygen consumption
    ½É±Ù»ê¼Ò ¼Òºñ·®(¡­ß«áÈá¼Þ¨åÖ).
  • oxygen consumption
    »ê¼Ò¼Ò¸ð
  • oxygen consumption
    »ê¼Ò¼Ò¸ð(·®) (¡­á¼ÙÄåÖ).
  • phthisis =consumption ³ª
    °áÇÙ(Ì¿ú·), ³ë( ).
  • water consumption
    ¹°¼Òºñ·®(ÊÙËÛË×Ëâ), ±Þ¼ö·®(Ë»ËàËâ).
  • antibody, complement binding
    º¸Ã¼°áÇÕÇ×ü
  • antibody, complement fixing
    º¸Ã¼°áÇÕÇ×ü
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Ames test
    ¿¡ÀÓÁî °Ë»ç¹ý
  • antiglobulin test
    Ç×(ù÷)±Û·ÎºÒ¸° ½ÃÇè(ù÷ô÷ãËúÐ)
  • Aschheim-Zondek test
    ¾Æ»þÀÓ-Á¸µ¦ ½ÃÇè(ãËúÐ)
  • Ascoli test
    ¾Æ½ºÄݸ® ½ÃÇè(ãËúÐ)
  • Barfoed's test
    ¹Ù¸£ÆÐµå ½ÃÇè(ãËúÐ)
  • benzidine test
    º¥Áöµò½ÃÇè(ãËúÐ)
  • blind test
    ¸Í°Ë(ØîËþ)
  • Bradshaw test
    ºê·¡µå¼î¿ì ½ÃÇè(ãËúÐ)
  • capon test
    °Å¼¼(ËÛá§)´ß ½ÃÇè(ãËúÐ)
  • carbohydrate tolerance test
    ´çÁú ºÎÇϽÃÇè(ÓØòõݶùÃãËúÐ)
  • carbon clearance test
    ź¼Ò ûÁ¤½ÃÇè(÷©áÈôèïäãËúÐ)
  • cephalin-cholesterol flocculation test
    ¼¼ÆÈ¸°-ÄÝ·¹½ºÅ×·Ñ ¸é»ó½ÃÇè(ØúßÒãËúÐ)
  • chronic toxicity test
    ¸¸¼º µ¶¼º½ÃÇè(Ø·àõÔ¸àõãËúÐ)
  • cis-trans test
    ½Ã½ºÆ®¶õ½º ½ÃÇè(ãËúÐ)
  • comb growth test
    °è°ü ¼ºÀå½ÃÇè(ͮήà÷íþãËúÐ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • pulmonary function test
    Æó±â´É°Ë»ç
  • qualitative test
    Á¤¼º½ÃÇè
  • respiratory function test
    È£Èí±â´É°Ë»ç
  • routine test
    »ó¿ë Å×½ºÆ®
  • screening test
    ¼±º°°Ë»ç, ¿¹ºñ°Ë»ç
  • serologic test
    Ç÷û(ÇÐÀû)°Ë»ç
  • sigle blind test
    ´ÜÀϸͽÃÇè
  • skin test
    ÇǺÎ(¹ÝÀÀ)°Ë»ç
  • supression test
    ¾ïÁ¦°Ë»ç
  • test
    ½ÃÇè, °Ë»ç(¹ý)
  • test object
    ½ÃÇè´ë»ó, Ç¥½Ä¹°
  • test phantom
    Ç¥ÁØÆÒÅÒ
  • test phase
    ½ÃÇè±â
  • thymol turbidity test
    Ƽ¸ôȥʽÃÇè
  • thyroid function test
    °©»ó¼±±â´É°Ë»ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CRL cell repository line; Certified Record Librarian; complement receptor location; complement receptor ...
CF test Complement Fixation test; º¸Ã¼°áÇÕ¹ý
CCAT chick cell agglutination test; conglutinating complement absorption test
CFT cardiolipin flocculation test; clinical full time; complement-fixation test
Bz-Ty-PABA test N-Benzoyl-L-Tyrosyl-p-Amino-Benzoic Acid test
  = Bentiromide test
  = Tr...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
NFCS Nationwide Food Consumption Survey
QO(2) O(2) consumption
VO(2) O(2) consumption
peak VO2 Peak oxygen consumption
VO2 Ventilation and oxygen consumption
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • abrasion test
    ¸¶¸ê ½ÃÇè
    ¸¶¸ð¿¡ °ßµð´Â Á¤µµ¸¦ ½ÃÇèÇÏ´Â °Ë»ç.
  • acetest tablet test
    ¾Æ¼¼Å×½ºÆ® Á¤ ½ÃÇè
    ¹éÁö À§¿¡ ¿Ã·Á³õÀº ¾Æ¼¼Å×½ºÆ® Á¤¿¡ ¿ä ÇÑ ¹æ¿ïÀ» ¶³¾î¶ß¸± ¶§, ¾î´À Á¤µµÀÇ ¾Æ¼¼ÅæÀÌ Á¸ÀçÇÏ¸é ±× ¾ç¿¡ µû¶ó¼­ ¾Æ¼¼Å×½ºÆ® Á¤ÀÌ ´ãÀÚ»ö
  • acetoacetic acid test
    ¾Æ¼¼Åä ÃÊ»ê ½ÃÇè
  • achievement test
    ¼öµæ´É·Â °Ë»ç, ¼öµæ´É·Âµµ °Ë»ç
  • acid elution test
    »ê ¿ë¸® ½ÃÇè
    ÅÂ¾Æ Çì¸ð±Û·ÎºóÀÇ °ËÃâ ½ÃÇèÀ¸·Î, ½½¶óÀÌµå ±Û¶ó½º À§¿¡ °ø±â °ÇÁ¶µÈ Ç÷¾× µµÆ÷ Ç¥º»À» 80% ¸ÞŸ³î·Î °íÁ¤ÇÏ¿©,
  • acoustic reflex test
    û°¢¹Ý»ç ½ÃÇè
    û°¢¹Ý»ç ¿ªÄ¡ÀÇ ÃøÁ¤¹ýÀ¸·Î¼­ Àüµµ¼º°ú °¨°¢½Å°æ¼º ³­Ã»À» °¨º° Áø´ÜÇϰųª û½Å°æÁ¾À» Áø´ÜÇÏ´Â µ¥ ÀÌ¿ëµÈ´Ù.
  • ACTH stimulation test
    ACTH ÀÚ±Ø °Ë»ç
    Çϼöü ºÎ½ÅÇÇÁú°è ¿¹ºñ·Â°Ë»çÀÇ Çϳª. ºÎ½ÅÇÇÁúÀÚ±Ø È£¸£¸ó
  • Addis test
    ¾Æµð½º ½ÃÇè
    12½Ã°£ µ¿¾È ¿äÀÇ ÀÏÁ¤·® Áß ÀûÇ÷±¸ ¼ö, ¹éÇ÷±¸ ¼ö, »óÇǼ¼Æ÷, ¿øÁÖ, ´Ü¹é ÇÔ·®ÀÇ ÃøÁ¤. ½ÅÀå ÁúȯÀÇ Áø´Ü°ú °ü¸®¿¡ »ç¿ëµÈ´Ù.
  • additional diagnostic test
    ºÎ°¡Àû Áø´Ü¹ý
  • Adler's test
    ¾Æµé·¯ ½ÃÇè
    µ¿ÀǾî=benzidine test. º¥ÁöµòÀÇ ºùÃÊ»ê Æ÷È­ ¿ë¾×¿¡ °°Àº ¾çÀÇ 3% °ú»êÈ­¼ö¼Ò¿Í ÇÇ°Ë¾× 1 §¢¸¦ °¡ÇÏ¿© û»öÀÌ »ý±â¸é Ç÷¾×ÀÌ Á¸ÀçÇÏ´Â °ÍÀÌ´Ù.
  • adsorption test
    ÈíÂø ½ÃÇè
  • agglutination test
    ÀÀÁý ½ÃÇè
  • agglutinin absorption test
    ÀÀÁý¼Ò Èí¼ö ½ÃÇè
    ¸é¿ª Ç÷û Áß¿¡ ÇÔÀ¯µÇ¾î ÀÖ´Â ºÒÇÊ¿äÇÑ ÀÀÁý¼Ò¸¦ Á¦¿ÜÇϰí, ƯÁ¤ÇÑ ÀÀÁý¼Ò¸¸À» ÇÔÀ¯ÇÏ´Â ÀÎÀÚ Ç÷ûÀ» ¸¸µå´Â ¹æ¹ý. ¸é¿ª Ç÷û¿¡ ÇÊ¿äÇÑ ÀÀÁý¼Ò¿¡ ´ëÇÑ ÀÀÁý¿ø
  • air test
    °ø±â ½ÃÇè
  • alkali denaturation test
    ¾ËÄ®¸® º¯¼º ½ÃÇè
    žƼº Çì¸ð±Û·ÎºóÀÇ ³óµµ¸¦ ÃøÁ¤ÇÏ´Â ºÐ±¤ºñ»ö¹ýÀ¸·Î, °¨µµ´Â ÁßÁ¤µµÀÌ´Ù. ÀÌ ½ÃÇèÀº Çì¸ð±Û·Îºó ºÐÀÚ°¡ ¾ËÄ®¸®¿¡ ³ëÃâµÇ¾úÀ» ¶§ ±Û·Îºó ºÎºÐÀÇ º¯¼º¿¡ ´ëÇÑ Çì¸ð±Û·Îºó ºÐÀÚÀÇ ÀúÇ×µµ¿¡ ´Þ·Á ÀÖ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
complement 1s <enzyme> The activated form of complement 1 which has hydrolase activity. In the classical pathway, it splits first c4 and then c2 into active components, thereby generating a new enzyme referred to as eac142 or c42 or c3 convertase.
Registry number: EC 3.4.21.42
(12 Dec 1998)
complement 2 The third component in the complement reaction sequence. It is a beta-globulin with a molecular weight of 117,000, a serum concentration of 30 micrograms/ml and a sedimentation coefficient of 4. It activates c3.
(12 Dec 1998)
complement 3 The fourth component to attach in the complement reaction sequence. It is a beta-globulin with a sedimentation coefficient of 5.5, a molecular weight of 185,000 and a serum concentration of 1.3 micrograms/ml. Its fragments have anaphylatoxic, chemotactic, and histaminic action and affect smooth muscle.
(12 Dec 1998)
complement 3a <chemical> Smaller fragment formed when c3 convertase splits c3 into c3a and c3b. C3a is a 77-amino acid peptide that includes a carboxy-terminal arginine which is crucial for its biological activities. C3a causes symptoms of immediate hypersensitivity (anaphylaxis) including smooth muscle contraction, mast cell histamine release, and local inflammation. It is considered an anaphylatoxin along with c4a, c5a, and c5a des-arginine.
Chemical name: Complement C3a
(12 Dec 1998)
complement 3b <chemical> The larger fragment formed when c3 convertase splits c3 into c3a and c3b. In both the classical and alternate pathway, c3b participates in immune adherence and enhances phagocytosis. It also forms a cellular intermediate which continues the complement process. In the alternate pathways, c3b initiates a positive feedback activation of c3pase.
Chemical name: Complement C3b
(12 Dec 1998)
complement 3b inactivators Compounds which inhibit, antagonise, or inactivate complement 3b. A well-known inhibitor is a beta-globulin which cleaves c3b into inactive fragments c3c and c3d. C3bina plays a key role in the regulation of the complement system by blocking the cytolytic sequence and preventing recruitment of the properdin amplification loop.
(12 Dec 1998)
complement 3c <chemical> An inactivated form of complement 3b (c3b). Complement 3b is inactivated with the help of two regulatory factors, complement factor h and complement factor I. Complement factor h (c3b inactivator accelerator) makes c3b susceptible to the serine protease, complement factor I (formerly called kaf, c3binf, or enzyme 3b inactivator), to form ic3b. Then complement factor I and a trypsin-like proteolytic enzyme further cleave ic3b into c3c and c3dg.
Chemical name: Complement C3c
(12 Dec 1998)
complement 3 convertase <enzyme> The enzyme which in both the classical and alternate complement pathways cleaves complement 3 into anaphylatoxin (c3a) and c3b.
Registry number: EC 3.4.21.43
(12 Dec 1998)
complement 3d <chemical> An inactivated fragment of complement 3b (c3b). Factor h makes c3b susceptible to factor I (formerly called kaf, c3binf, or enzyme 3b inactivator) to form ic3b. Then factor I and a trypsin-like proteolytic enzyme further cleave ic3b into c3c and c3dg. Serum proteases degrade c3dg into complement 3d (c3d) and c3g.
Chemical name: Complement C3d
(12 Dec 1998)
complement 3 nephritic factor A magnesium-dependent IgG autoantibody found in serum of patients with chronic mesangioproliferative hypocomplementemic glomerulonephritis. It causes inactivation of c3 in the alternate pathway by cleaving c3 into two inactive fragments, c3c and c3d, instead of the normal c3b.
(12 Dec 1998)
complement 4 The second component to react in the complement sequence. It is a beta-globulin with a sedimentation coefficient of 18.7, a molecular weight of 240,000 and a serum concentration of 430 micrograms/ml. It is activated by complement 1 and serves as a receptor for c2.
(12 Dec 1998)
complement 4a <chemical> Smaller fragment formed when c1s splits c4 into c4a and c4b. As an anaphylatoxin, c4a causes symptoms of immediate hypersensitivity but it has weaker activity than c3a or c5a.
Chemical name: Complement C4a
(12 Dec 1998)
complement 4b <chemical> Larger fragment formed when c1s splits c4 into c4a and c4b. C4b combines with c2b to form the activated c4b2b complex which is often called the classical pathway c3 convertase.
Chemical name: Complement C4b
(12 Dec 1998)
complement 5 The fifth component in the complement reaction sequence, probably exists in a complex with c6 and c7. It is a beta-globulin with a sedimentation coefficient of 10, serum concentration of 75 micrograms/ml and molecular weight of 180,000. It is activated by c423 and releases fragments with anaphylatoxic, chemotactic, and histamine-releasing actions and affecting smooth muscle.
(12 Dec 1998)
complement 5a <chemical> Smaller fragment formed when c5 convertase splits c5 into c5a and c5b. C5a is a 74-amino acid peptide that includes a carboxy-terminal arginine crucial for its spasmogenic activity and a carbohydrate moiety. C5a is the most potent anaphylatoxin mediating immediate hypersensitivity.
Chemical name: Complement C5a
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • New Test.
    New Testament
  • Partial Test Ban Treaty
    ºÎºÐÀû ÇÙ½ÇÇè ±ÝÁö Á¶¾à
  • Rorschach test
    ·Î¸£»þÇÏ Å×½ºÆ®(À×Å©ÀÇ ¾ó·è°£Àº ¹«ÀǹÌÇÑ ¹«´Ì¸¦ ÇØ¼®½ÃÄÑ »ç¶÷ÀÇ ¼º°ÝµîÀ» ¾Ë¾Æ³»´Â °Ë»ç)
  • Wassermann test
    ¹Ù¼­¸¸ °Ë»ç(¹ÝÀÀ);¸Åµ¶ÀÇ Ç÷û Áø´Ü
  • achievement test
    Çз°˻ç
  • acid test
    »ê½ÃÇè;¾ö¹ÐÇѽÃÇè
  • alpha test
    Áö´ÉÅ×½ºÆ®
  • blood test
    Ç÷¾×°Ë»ç
  • breath test
    ÁÖ±â°Ë»ç
  • captive test (firing)
    (¹Ì»çÀÏ.·ÎÄÏ ¿£ÁøµîÀÇ)Áö»ó ºÐ»ç ½ÃÇè
  • cartoon test
    ¾àÈ­ Å×½ºÆ®
  • completion test
    ¿Ï¼ºÇü Å×½ºÆ®
  • doping test
    ±ÝÁö ¾à¹° °Ë»ç
  • doublebline test
    ÀÌÁß¸Í °Ë»ç¹ý(½Å¾à È¿°úÀÇ °Ë»ç¹ý)
  • driving test
    ¿îÀü ¸éÇã ½ÃÇè
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á